Related Experiment Video
Updated: Mar 26, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
Lysosomes as mediators of drug resistance in cancer
Benny Zhitomirsky1, Yehuda G Assaraf1
1The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Abstract:
Drug resistance remains a leading cause of chemotherapeutic treatment failure and cancer-related mortality. While some mechanisms of anticancer drug resistance have been well characterized, multiple mechanisms remain elusive. In this respect, passive ion trapping-based lysosomal sequestration of multiple hydrophobic weak-base chemotherapeutic agents was found to reduce the accessibility of these drugs to their target sites, resulting in a markedly reduced cytotoxic effect and drug resistance. Recently we have demonstrated that lysosomal sequestration of hydrophobic weak base drugs triggers TFEB-mediated lysosomal biogenesis resulting in an enlarged lysosomal compartment, capable of enhanced drug sequestration. This study further showed that cancer cells with an increased number of drug-accumulating lysosomes are more resistant to lysosome-sequestered drugs, suggesting a model of drug-induced lysosome-mediated chemoresistance. In addition to passive drug sequestration of hydrophobic weak base chemotherapeutics, other mechanisms of lysosome-mediated drug resistance have also been reported; these include active lysosomal drug sequestration mediated by ATP-driven transporters from the ABC superfamily, and a role for lysosomal copper transporters in cancer resistance to platinum-based chemotherapeutics. Furthermore, lysosomal exocytosis was suggested as a mechanism to facilitate the clearance of chemotherapeutics which highly accumulated in lysosomes, thus providing an additional line of resistance, supplementing the organelle entrapment of chemotherapeutics away from their target sites. Along with these mechanisms of lysosome-mediated drug resistance, several approaches were recently developed for the overcoming of drug resistance or exploiting lysosomal drug sequestration, including lysosomal photodestruction and drug-induced lysosomal membrane permeabilization. In this review we explore the current literature addressing the role of lysosomes in mediating cancer drug resistance as well as novel modalities to overcome this chemoresistance.
Insights
Lysosomes sequester chemotherapy drugs, causing cancer drug resistance. Targeting lysosomal drug sequestration offers new strategies to overcome this resistance and improve treatment outcomes.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Drug resistance is a major challenge in cancer chemotherapy, leading to treatment failure and mortality.
- While some drug resistance mechanisms are known, others, particularly lysosome-mediated resistance, are still being uncovered.
- Lysosomal sequestration of hydrophobic weak-base chemotherapeutics reduces drug efficacy by limiting access to target sites.
Purpose of the Study:
- To review the multifaceted role of lysosomes in mediating cancer drug resistance.
- To explore novel therapeutic strategies aimed at overcoming lysosome-mediated chemoresistance.
- To elucidate the mechanisms by which lysosomes contribute to treatment failure in cancer therapy.
Main Methods:
- Literature review of current research on lysosome-mediated drug resistance in cancer.
- Analysis of mechanisms including passive ion trapping, active transport, and lysosomal exocytosis.
- Examination of emerging therapeutic approaches targeting lysosomal drug sequestration.
Main Results:
- Lysosomal sequestration, triggered by hydrophobic weak-base drugs, leads to enlarged lysosomes and enhanced drug accumulation, promoting chemoresistance.
- Cancer cells with increased drug-accumulating lysosomes exhibit greater resistance to these agents.
- Other mechanisms include ATP-binding cassette (ABC) transporters, copper transporters, and lysosomal exocytosis.
Conclusions:
- Lysosomes play a critical role in multiple facets of cancer drug resistance.
- Targeting lysosomal drug sequestration, photodestruction, or membrane permeabilization presents promising avenues for overcoming chemoresistance.
- Understanding lysosome-mediated resistance is crucial for developing more effective cancer therapies.
More Related Videos
09:56Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Lysosomes
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...